OncoMatch/Clinical Trials/NCT04776330
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Is NCT04776330 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BCMA targeted prime CAR-T cells for multiple myeloma.
Treatment: BCMA targeted prime CAR-T cells — This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA expression (cell membrane expression)
Evidence for cell membrane BCMA expression
Lab requirements
Kidney function
creatinine clearance≤2 x ULN
Liver function
ALT/AST≤3 x ULN and bilirubin≤2 x ULN
Cardiac function
Left ventricular ejection fraction ≥50%
Left ventricular ejection fraction ≥50%; Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN; Sufficient renal function defined by creatinine clearance≤2 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify